João Pedro Ferreira Selected Research

Spironolactone (Aldactone)

4/2022	Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT.
1/2022	Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial.
1/2022	Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
1/2022	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.
1/2022	The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
11/2021	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
1/2021	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
1/2021	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension.
1/2021	Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial.
12/2020	Estimating the Lifetime Benefits of Treatments for Heart Failure.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

João Pedro Ferreira Research Topics

Disease

116	Heart Failure 10/2022 - 10/2013
24	Myocardial Infarction 04/2022 - 02/2017
13	Fibrosis (Cirrhosis) 01/2022 - 01/2018
12	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2020
12	Stroke (Strokes) 10/2021 - 08/2016
10	Hypertension (High Blood Pressure) 11/2021 - 10/2017
9	Left Ventricular Dysfunction 04/2022 - 01/2018
8	Atrial Fibrillation 04/2022 - 08/2016
7	Inflammation (Inflammations) 01/2022 - 01/2019
6	Hyperkalemia 01/2022 - 01/2018
6	Acute Coronary Syndrome 01/2021 - 01/2018
6	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 05/2017
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 01/2018
5	Respiratory Sounds (Crackle) 01/2022 - 05/2019
4	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2022 - 11/2019
4	Hypotension (Low Blood Pressure) 01/2021 - 01/2020
4	Chronic Renal Insufficiency 01/2021 - 11/2016
4	Hemorrhage 01/2021 - 08/2016
4	Diabetes Mellitus 01/2021 - 05/2017
3	Chronic Obstructive Pulmonary Disease (COPD) 10/2022 - 01/2020
3	Prediabetic State (Prediabetes) 08/2022 - 01/2021
3	Cardiomyopathies (Cardiomyopathy) 01/2022 - 01/2016
3	Systolic Heart Failure 01/2021 - 01/2018
3	Renal Insufficiency (Renal Failure) 01/2021 - 01/2019
3	Albuminuria 01/2021 - 03/2014
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2021 - 01/2017
2	COVID-19 01/2022 - 02/2021
2	Neoplasms (Cancer) 01/2022 - 01/2019
2	Obesity 01/2022 - 01/2020
2	Gout 01/2022 - 01/2022
2	Isolated Systolic Hypertension 11/2021 - 07/2021
2	Anemia 01/2021 - 01/2018
2	ST Elevation Myocardial Infarction 02/2020 - 01/2018
2	Hypokalemia 01/2020 - 01/2020
1	Weight Gain 04/2022
1	Weight Loss (Weight Reduction) 04/2022
1	Hyponatremia 04/2022
1	Body Weight (Weight, Body) 04/2022
1	Hypernatremia 04/2022
1	Non-alcoholic Fatty Liver Disease 03/2022
1	Overweight 01/2022
1	Hypertrophy 01/2022
1	Necrosis 01/2022

Drug/Important Bio-Agent (IBA)

28	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2014
28	empagliflozinIBA 10/2022 - 01/2019
21	Spironolactone (Aldactone)FDA LinkGeneric 04/2022 - 03/2014
18	Eplerenone (Inspra)FDA LinkGeneric 04/2022 - 01/2018
17	Brain Natriuretic Peptide (Natrecor)FDA Link 10/2022 - 03/2014
15	Mineralocorticoid Receptor AntagonistsIBA 01/2022 - 01/2014
10	pro-brain natriuretic peptide (1-76)IBA 10/2022 - 01/2018
10	SodiumIBA 04/2022 - 06/2016
10	CreatinineIBA 02/2021 - 11/2016
9	DiureticsIBA 04/2022 - 10/2013
9	PotassiumIBA 01/2022 - 01/2018
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2019
8	Natriuretic PeptidesIBA 01/2022 - 12/2016
7	Pharmaceutical PreparationsIBA 03/2022 - 01/2011
7	CollagenIBA 01/2022 - 01/2018
6	AlbuminsIBA 10/2022 - 01/2018
6	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2020
5	Procollagen Type IIBA 01/2022 - 01/2019
5	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 01/2020
5	alogliptinIBA 07/2021 - 01/2020
5	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 06/2021 - 01/2019
4	Insulin (Novolin)FDA Link 10/2022 - 04/2019
4	Troponin T (Troponin T1)IBA 10/2022 - 01/2014
4	Collagen Type III (Type III Collagen)IBA 01/2022 - 01/2019
4	Sodium-Glucose Transport ProteinsIBA 01/2022 - 01/2021
4	procollagen Type III-N-terminal peptide (PIIP)IBA 01/2022 - 01/2019
4	Antihypertensive Agents (Antihypertensives)IBA 11/2021 - 05/2017
4	TroponinIBA 07/2021 - 01/2014
4	Angiotensin Receptor AntagonistsIBA 06/2021 - 01/2019
4	RivaroxabanIBA 01/2021 - 11/2019
4	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2021 - 01/2020
4	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2020 - 06/2016
3	Collagen Type I (Type I Collagen)IBA 01/2022 - 01/2021
3	Uric Acid (Urate)IBA 01/2022 - 10/2020
3	procollagen type I carboxy terminal peptide (PICP)IBA 01/2022 - 01/2019
3	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2021 - 01/2020
3	Hemoglobins (Hemoglobin)IBA 01/2021 - 04/2016
3	Valsartan (Vals)FDA Link 01/2021 - 01/2018
3	AldosteroneIBA 01/2020 - 01/2018
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2022
2	dapagliflozinIBA 11/2021 - 01/2020
2	omega-Chloroacetophenone (Mace)IBA 10/2021 - 02/2021
2	Biological ProductsIBA 02/2021 - 01/2020
2	SymportersIBA 01/2021 - 01/2021
2	Neprilysin (Neutral Endopeptidase)IBA 01/2021 - 01/2020
2	Losartan (Cozaar)FDA LinkGeneric 01/2021 - 01/2018
2	Matrix Metalloproteinases (MMPs)IBA 01/2021 - 04/2015
2	Triglycerides (Triacylglycerol)IBA 11/2020 - 01/2018
2	CholesterolIBA 01/2020 - 01/2019
2	Carvedilol (Coreg)FDA LinkGeneric 01/2020 - 01/2018
2	AnticoagulantsIBA 11/2016 - 08/2016
1	MagnesiumIBA 02/2022
1	C-Reactive ProteinIBA 01/2022
1	Genetic Markers (Genetic Marker)IBA 01/2022
1	LigandsIBA 01/2022
1	Fenofibrate (CiL)FDA LinkGeneric 01/2022

Therapy/Procedure

40	Therapeutics 08/2022 - 10/2013